The role of dopaminergic medication, lipid, and endocannabinoid pathway alterations in idiopathic and -mediated Parkinson’s disease – a large-scale targeted metabolomics study

Alexander Balck,Max Borsche,Philip Campbell,Xi Luo,John Harvey,Theresa Brückmann,Charlotte Ludwig,Amy Harms,Katja Lohmann,Huw R Morris,Anthony H Schapira,Thomas Hankemeier,Ronan Fleming,Silke Szymczak,Christine Klein

DOI: https://doi.org/10.1101/2024.03.01.24303613

2024-03-02

Abstract:Alterations in many metabolites and biochemical pathways have been described in Parkinson’s Disease (PD). However, only a small fraction of these have been replicated in independent studies. As almost every PD patient is treated with dopaminergic medication, it is challenging to discriminate between disease- and drug-related effects, especially in relation to dopamine metabolism. We conducted a large-scale metabolomic study in plasma from 140 idiopathic (IPD), 19 -linked PD patients, and 64 healthy controls to disentangle disease-related metabolite alterations from drug-related effects. We distinguished between L-Dopa and non-L-Dopa treated PD patients to uncover nuanced metabolic changes associated with different therapies. We demonstrate that L-Dopa treatment uniquely influences the metabolome, with methyldopa and methoxytyramine, both L-Dopa breakdown products, elevated in L-Dopa-treated IPD and -linked PD patients. These alterations were not seen in untreated IPD patients and those on agonist treatment only. Polyamine metabolism alterations, notably elevation of putrescine and ornithine, were partly caused by L-Dopa treatment but also found in non-L-Dopa treated PD patients. In non-L-Dopa-treated patients, endocannabinoid metabolites were lowered and associated with disease duration. We observed lipid metabolism alterations, highlighting potential crosslinks with alpha-synuclein and providing insights into pathophysiological mechanisms. All linked PD patients received L-Dopa treatment. However, our data potentially support the well-established role of oxidative damage in these subtypes of PD. In conclusion, our study emphasizes the significant impact of L-Dopa treatment on the metabolome, which might be of relevance not only for metabolomics studies but also for PD biomarker research in general. Finally, our study highlights potential biomarkers and pathways crucial for the understanding disease mechanisms of PD.

Neurology

What problem does this paper attempt to address?

The problems that this paper attempts to solve mainly focus on the following aspects:

1. **Distinguishing between disease - related and drug - related metabolite changes**:
- The paper points out that almost all Parkinson's Disease (PD) patients will receive dopaminergic drug treatment, which makes it very difficult to distinguish which metabolite changes are caused by the disease itself and which are caused by the drugs. Therefore, researchers hope to unravel these complex metabolic changes through large - scale targeted metabolomics research, especially the impact on dopamine metabolism.

2. **Exploring metabolic differences under different treatment methods**:
- Researchers are particularly interested in the impact of L - Dopa treatment on the metabolome and compare it with PD patients who have not received L - Dopa treatment and those who have only received dopamine receptor agonist treatment. The aim is to reveal the specific changes of metabolites under different treatment methods, so as to better understand the impact of drugs on metabolic pathways.

3. **Identifying metabolic markers independent of dopaminergic drugs**:
- In addition to exploring the impact of drugs on metabolism, researchers also aim to identify metabolites that are not affected by dopaminergic drugs. These metabolites may be of great value in the diagnosis and mechanism research of PD. Especially for idiopathic PD (IPD) and PD caused by PRKN or PINK1 gene mutations (PRKN/PINK1 - linked PD), researchers hope to find metabolic markers that can distinguish these different subtypes.

4. **Exploring changes in lipid and endogenous cannabinoid pathways**:
- Researchers also focus on changes in lipid metabolism and endogenous cannabinoid pathways, which may play an important role in the pathophysiological mechanism of PD. By analyzing the metabolite changes in these pathways, researchers hope to provide new insights into the pathogenesis of PD.

5. **Evaluating the application of metabolomics in PD biomarker research**:
- Finally, researchers hope to emphasize the significant impact of L - Dopa treatment on the metabolome through this study and discuss the significance of this finding for metabolomics research and PD biomarker development.

In summary, the main objective of this paper is to distinguish disease - related and drug - related metabolic changes in PD patients, identify potential biomarkers, and provide new clues for the pathogenesis of PD through large - scale targeted metabolomics research.